CSL is one of three Tier 1 plasma therapy companies that benefit from an oligopoly in a highly consolidated market. All the players are vertically integrated as plasma sourcing is a key constraint in production. The plasma sourcing market is currently in short supply, however, CSL is well positioned having invested significantly in plasma collection centers, owning roughly 30% of collection centers globally.
CSL is investing in both physical capacity and R&D, leaving it well-positioned to take advantage of growth opportunities in the key immunoglobulins market.
Areas of the plasma industry could be replaced by newer therapies, which would leave CSL overinvested in plasma collection and fractionation capacity that will be hard to repurpose.
|
Metric
|
CSL
|
SNY
|
GRF.P
|
|---|---|---|---|
Price/Earnings (Normalized) | 28.13 | 9.64 | 26.42 |
Price/Book Value | 5.22 | 1.50 | 0.73 |
Price/Sales | 6.26 | 2.29 | 0.65 |
Price/Cash Flow | 32.65 | 11.20 | 7.39 |
|
Metric
|
CSL
|
SNY
|
GRF.P
|
|---|---|---|---|
Quick Ratio | 0.95 | 0.83 | 0.72 |
Current Ratio | 2.15 | 1.27 | 2.48 |
Interest Coverage | 7.21 | 11.03 | 1.28 |
|
Metric
|
CSL
|
SNY
|
GRF.P
|
|---|---|---|---|
Return on Assets (Normalized) | 8.11% | 8.05% | 1.17% |
Return on Equity (Normalized) | 18.17% | 14.38% | 4.22% |
Return on Invested Capital (Normalized) | 10.94% | 10.85% | 3.28% |
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Fhxrwjxdj | Dmtrr | $553.3 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Mcqxskrr | Csnnvq | $101.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Hxstfhcd | Lmllgm | $98.9 Bil | |
MRNA
| Moderna Inc | Dzkllxq | Fvpj | $39.7 Bil | |
ARGX
| argenx SE ADR | Fmlnxqkr | Cfpf | $21.5 Bil | |
BNTX
| BioNTech SE ADR | Vdtmyfjgh | Vywm | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Gfvsfnybv | Llzgx | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Zmqlygfyl | Hmycgbj | $17.2 Bil | |
RPRX
| Royalty Pharma PLC Class A | Rpkfnkdsp | Zxtrzkf | $12.3 Bil | |
INCY
| Incyte Corp | Ltjphxdj | Jzxbq | $11.8 Bil |
